FGFR Inhibitor AZD4547

Search with Google Search with Bing

Information
Drug Name
FGFR Inhibitor AZD4547
Description
Entry(CIViC)
3
CIViC
Disease Mutation EL ET ED CS VO TR Pubmed Links
stomach carcinoma FGFR2 AMPLIFICATION
( ENST00000457416.7 ) FGFR2 AMPLIFICATION
( ENST00000457416.7 ) 		B Predictive Supports Sensitivity/Response N/A 3 27179038 Detail
breast cancer FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		C Predictive Supports Sensitivity/Response N/A 2 27179038 Detail
sarcoma FGFR1 EXPRESSION FGFR1 EXPRESSION D Predictive Supports Sensitivity/Response Somatic 3 27535980 Detail
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
Nine patients with FGFR2-amplified gastroesophagea... FGFR2 FGFR2 AMPLIFICATION
( ENST00000457416.7 ) FGFR2 AMPLIFICATION
( ENST00000457416.7 ) 		Sensitivity true CIViC Evidence detail
Activity of the FGFR-selective inhibitor AZD4547 i... FGFR1 FGFR1 AMPLIFICATION
( ENST00000425967.8 ) FGFR1 AMPLIFICATION
( ENST00000425967.8 ) 		Sensitivity true CIViC Evidence detail
Targeting of FGFR1 by RNA interference and small-m... FGFR1 FGFR1 EXPRESSION FGFR1 EXPRESSION Sensitivity true CIViC Evidence detail
NCT ID Status Phase Summary Start date Completion date
NCT02154490 Completed Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer July 8, 2014 April 15, 2022
NCT02965378 Completed Phase 2/Phase 3 Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer October 2014 October 2019
NCT04439240 Completed Phase 2 Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W) May 31, 2016 June 30, 2020